Walking Tall, But Watch the Blisters With This Sandal Stock

The brand behind the world’s favorite sandals just raised the bar on revenue, added a new facility, and kept guidance intact. We now have to weigh if the stock deserves fresh legs.

Imagine a company that’s blending pharma, wellness, and telehealth — and now adding a bold twist by building a digital asset reserve.

It’s scaling distribution across Europe and the U.S., pushing premium wellness products into fast-growing global markets, and even signing new international deals in the Middle East.

At the same time, it’s diversifying into one of the fastest-growing digital assets on the planet, creating a rare dual-play growth story.

This could be the kind of high-upside small-cap that investors whisper about before the crowd catches on.

Get the full story + ticker here.

Wall Street’s tiptoeing into Thursday. Dow futures down a hair, the S&P is basically frozen, and the Nasdaq’s inching lower as AI darlings like Oracle and Nvidia keep sliding.

Everyone’s bracing for jobless claims, the one number that could flip the Fed from “soft landing” to “hard hat required.” Until then, traders are stuck in limbo, watching record-high valuations wobble like Jenga towers.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Premarket Earnings:

Aftermarket Earnings:

Economic Reports:

Lithium Americas (NYSE: LAC) ripped like a dune buggy this week, nearly doubling on chatter that Washington might swap part of its giant DOE loan for an equity stake. Great headline, thin details.

TD Cowen quickly moved the name to Hold with a $5 target, reminding everyone the company is still pre-revenue and Thacker Pass won’t be selling battery juice until late this decade.

Yes, an anchor deal with a major automaker and a government backstop would help financing, but the economics didn’t suddenly change overnight. This is still a big capex project with permitting, ramp, and price-cycle risk, riding a sector that can whipsaw faster than a desert crosswind.

My Take For You: If you caught the move, scale some profits and leave a runner. If you missed it, don’t chase a sandstorm.

Let the dust settle and watch for real terms on any government participation, updated capex and timeline, and clarity on pricing floors in the supply agreement. Technically, a retest of the mid-$5s would be healthier than a straight vertical.

My Verdict: You can rent the volatility, not the company, but if you’re a long-term investor, wait for documents, not rumors. Speculative buy only on pullbacks with a strict stop, otherwise, watchlist it until funding and timelines are locked.

The software giant Microsoft (NASDAQ: MSFT) just broadened its AI bench, wiring Anthropic’s models into its enterprise assistant alongside its usual partner. That means fewer single-supplier headaches, more choice for admins, and a nudge to customers that Copilot is an AI platform, not a one-trick pony.

Early access is limited to certain agents and tenants, but the direction is clear. Stack the best model for the job, keep enterprises sticky, and turn AI usage into a durable subscription uplift. The risk is that inference isn’t free, competitive features ship weekly, and investors are already paying a premium for perfection.

My Take For You: If you own it, keep it core. The story is seat penetration, attach rates, and margin lift from AI copilots across the suite. New money can aim for entries on market wobbles or single-stock pullbacks.

Track disclosed Copilot adoption, gross margin trajectory with AI cost discipline, and whether multi-model support accelerates customer rollout.

My Verdict: Core hold for long-term compounders, it’s hard to avoid at this point. Buy on dips rather than green-chasing. The thesis is still operating leverage from AI inside the world’s most entrenched productivity bundle.

This brand's not Nike-and that's the point.

It's fast, tech-driven, and built for viral drops.

Now, it has equity backing from one of college sports' most iconic names.

Find out why Bama is betting on this company

The comfort icon Birkenstock Holding PLC (NYSE: BIRK) came out swinging in the last quarter. Prelim revenue for the year lands ahead of guidance and EBITDA margins stay firmly north of 31%.

Management also scooped up a large German facility on the cheap, adding future production and logistics space without waiting years for a ground-up build. That signals confidence in multi-year demand across sandals, clogs, and footbeds, and it de-risks bottlenecks that have pinched premium brands before.

Headwinds remain as euro exposure, a fickle global consumer, and fashion cycles that can turn faster than a strap buckle. But this is a category leader leaning into controlled growth with enviable unit economics.

My Take For You: If you’ve been nursing a red position, this is a chance to lighten only if it sprints into the high-40s with no pause. Otherwise, consider holding for the capacity and margin story.

Looking to enter the comfort zone? Build gradually below $50, and watch for confirmation in December’s full results. There will be new information on inventory turns, direct-to-consumer mix, and any slip in price integrity.

My Verdict: Accumulate on weakness, not euphoria. It’s a quality brand (no longer just for hippies) executing on supply while keeping margins chunky. Medium-term upside looks wearable, just don’t size it like a tech rocket.

Cipher just announced it’s not only mining Bitcoin but also moonlighting as an AI landlord. That means your mining rig is now also a server farm for rent. Traders loved it, the stock’s up nearly 200% this year and now sprinting to fresh highs. We think it might be worth closer to $8, but clearly no one told the chart.

This is like watching your crypto-obsessed cousin suddenly get into real estate. Cute, but the rent checks still depend on Bitcoin not tanking.

QURE’s gene therapy data for Huntington’s disease showed a 75% slowdown in progression, and the stock took off like it just found the cheat codes to biotech. Shares are up 160% YTD and traders are piling in like it’s the only pill on the shelf.

But let’s be real here. Biotech rallies often trade like caffeinated squirrels, up, down, sideways, repeat. An FDA filing could take this higher, but a hiccup and the whole thing trips.

Bloom went vertical this year, then Jefferies walked in and yelled “overpriced,” slapping a $31 target on a $69 stock. Cue the pullback. Down 20% in two days, the fuel cell hype train suddenly looks like it missed a station.

This is the classic “too much, too fast” chart. It was trading like hydrogen was the new oil, but now traders are wondering if they’ve been breathing their own exhaust.

When Michael Saylor bought Bitcoin, Wall Street called him reckless.

That move turned into one of the most profitable trades in corporate history. His stock jumped more than 10,000%. His balance sheet became a digital-asset vault.

But here’s the flaw in that model: Bitcoin is static. It doesn’t earn rewards.

This time, the playbook is running with an asset that is more powerful.

BNB fuels the world’s largest exchange. It cuts trading costs, anchors DeFi, powers stablecoin flows, and grows scarcer with every burn. And unlike Bitcoin, it can be staked to generate yield.

That means a treasury full of BNB isn’t just waiting for price appreciation. It’s producing cash flow through validator nodes and staking rewards.

One company has already built a $368 million position, making it the largest BNB treasury on earth.

Wall Street hasn’t noticed. But when it does, the premium will come fast.

Get the full story here before the crowd catches on.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.